We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
American BioScience presented data at the recent Cardiovascular Revascularization
Therapies Conference in Washington, D.C., on the SNAPIST-I trial (Systemic Nanoparticle
Paclitaxel for Treatment of In-Stent Restenosis) investigating the use of its
protein-engineered nanoparticle albumin bound paclitaxel (Coroxane) for the
treatment of restenosis following bare-metal stenting of coronary arteries.
GlycoGenesys recently initiated a Phase I/II dose-escalation clinical trial
of its cancer drug candidate GCS-100LE in patients with multiple myeloma, the
second most common hematologic, or blood, cancer.
Genzyme has announced that physicians have treated the first patients in a Phase
III clinical study to test the safety and efficacy of tolevamer, an investigational
polymer therapy for patients with Clostridium difficile associated diarrhea
(CDAD), a form of infectious diarrhea caused by the bacterium C. difficile.
Cell Therapeutics has announced that a Phase III study of Trisenox consolidation
treatment in patients with newly diagnosed acute promyelocytic leukemia (APL)
completed enrollment with approximately 500 patients.
The FDA has approved Mylan Pharmaceuticals' abbreviated new drug application
for quinapril HCl and hydrochlorothiazide tablets in 10-mg/12.5-mg, 20-mg/12.5-mg
and 20-mg/25-mg strengths.
Cytogen, a product-driven biopharmaceutical company, has announced a new clinical
development initiative for a targeted oncology product designed to treat prostate
and other cancers.
Hemosol has negotiated an agreement with Biomedical Frontiers (BMF), a private
biopharmaceutical company located in Minneapolis, under which Hemosol will produce
two separate iron-binding drugs (40SD02 and 25SD04).
American Pharmaceutical Partners has announced that American BioScience initiated
enrollment in a Phase II study of Abraxane administered weekly in combination
with Herceptin in first-line treatment of metastatic breast cancer.